|
|
Article: Iomai's Patch For Flu Vaccine Fails To Beat Injected Version.
- Article from:
- BIOWORLD Today
- Article date:
- November 3, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
West Coast Editor
Iomai Corp.'s Phase I flop with its influenza-vaccine patch knocked shares down 40 percent, and sent researchers back to the drawing board - armed, at least, with data that their adjuvant to the vaccine, called LT, helped response.
At the end of trading Friday, Iomai's stock (NASDAQ:IOMI) traded at $2.54, down $1.70. The goal was to show the patch worked as well as injected vaccine, but the patch fell short.
Stanley Erck, president and CEO of Gaithersburg, Md.-based Iomai, told investors during a conference call that the company will keep working on its needle-free approach, possibly using a whole virus rather than the split ...